Literature DB >> 27959626

The Pathogenesis of Ebola Virus Disease.

Laura Baseler1, Daniel S Chertow2, Karl M Johnson3, Heinz Feldmann4, David M Morens5.   

Abstract

For almost 50 years, ebolaviruses and related filoviruses have been repeatedly reemerging across the vast equatorial belt of the African continent to cause epidemics of highly fatal hemorrhagic fever. The 2013-2015 West African epidemic, by far the most geographically extensive, most fatal, and longest lasting epidemic in Ebola's history, presented an enormous international public health challenge, but it also provided insights into Ebola's pathogenesis and natural history, clinical expression, treatment, prevention, and control. Growing understanding of ebolavirus pathogenetic mechanisms and important new clinical observations of the disease course provide fresh clues about prevention and treatment approaches. Although viral cytopathology and immune-mediated cell damage in ebolavirus disease often result in severe compromise of multiple organs, tissue repair and organ function recovery can be expected if patients receive supportive care with fluids and electrolytes; maintenance of oxygenation and tissue perfusion; and respiratory, renal, and cardiovascular support. Major challenges for managing future Ebola epidemics include establishment of early and aggressive epidemic control and earlier and better patient care and treatment in remote, resource-poor areas where Ebola typically reemerges. In addition, it will be important to further develop Ebola vaccines and to adopt policies for their use in epidemic and pre-epidemic situations.

Entities:  

Keywords:  Ebola; ebolavirus; epidemic; filovirus; viral disease pathogenesis; viral hemorrhagic fever

Mesh:

Year:  2017        PMID: 27959626     DOI: 10.1146/annurev-pathol-052016-100506

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  91 in total

1.  Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Authors:  John C Kash; Kathie-Anne Walters; Jason Kindrachuk; David Baxter; Kelsey Scherler; Krisztina B Janosko; Rick D Adams; Andrew S Herbert; Rebekah M James; Spencer W Stonier; Matthew J Memoli; John M Dye; Richard T Davey; Daniel S Chertow; Jeffery K Taubenberger
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

2.  Peripheral Neuronopathy Associated With Ebola Virus Infection in Rhesus Macaques: A Possible Cause of Neurological Signs and Symptoms in Human Ebola Patients.

Authors:  David X Liu; Donna L Perry; Timothy K Cooper; Louis M Huzella; Randy J Hart; Amanda M W Hischak; John G Bernbaum; Lisa E Hensley; Richard S Bennett
Journal:  J Infect Dis       Date:  2020-10-13       Impact factor: 5.226

3.  Differential requirements for FcγR engagement by protective antibodies against Ebola virus.

Authors:  Stylianos Bournazos; David J DiLillo; Arthur J Goff; Pamela J Glass; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 4.  Clinical Evaluation of Ebola Virus Disease Therapeutics.

Authors:  Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu
Journal:  Trends Mol Med       Date:  2017-08-17       Impact factor: 11.951

5.  The Crux of Ebola Diagnostics.

Authors:  James E Strong; Heinz Feldmann
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

Review 6.  Ebola Virus in the Democratic Republic of the Congo: Advances and Remaining Obstacles in Epidemic Control, Clinical Care, and Biomedical Research.

Authors:  Julie Erb-Alvarez; Aaron M Wendelboe; Daniel S Chertow
Journal:  Chest       Date:  2019-09-10       Impact factor: 9.410

Review 7.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 8.  COVID-19 challenge for modern medicine.

Authors:  Tomasz Dzieciatkowski; Lukasz Szarpak; Krzysztof J Filipiak; Milosz Jaguszewski; Jerzy R Ladny; Jacek Smereka
Journal:  Cardiol J       Date:  2020-04-14       Impact factor: 2.737

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  Molecular determinants of Ebola nucleocapsid stability from molecular dynamics simulations.

Authors:  Chaoyi Xu; Nidhi Katyal; Tanya Nesterova; Juan R Perilla
Journal:  J Chem Phys       Date:  2020-10-21       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.